Vytrus Biotech (XMAD:VYT) Marketable Securities: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:VYT Vytrus Biotech SA XMAD:VYT
69 GF Score
Price €17.40
GF Value €5.59
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech Marketable Securities?

Vytrus Biotech XMAD:VYT +2.35% 69 Marketable Securities is €0.00 Mil as of Dec. 2025. GuruFocus rates XMAD:VYT with a GF Score™ of 69/100 and a GF Value™ of €5.59 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Vytrus Biotech's Marketable Securities for the quarter that ended in Dec. 2025 was €0.00 Mil.

Vytrus Biotech's annual Marketable Securities stayed the same from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) and stayed the same from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Vytrus Biotech  (XMAD:VYT) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Vytrus Biotech Marketable Securities Related Terms

Vytrus Biotech Marketable Securities Historical Data

* Premium members only.

The historical data trend for Vytrus Biotech's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech Marketable Securities Chart

Vytrus Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Vytrus Biotech Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XMAD:VYT
69GF Score
Vytrus Biotech SA XMAD:VYT
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vytrus Biotech Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Vytrus Biotech (XMAD:VYT) has a Marketable Securities of €0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vytrus Biotech and its competitors.
Is Vytrus Biotech's Marketable Securities too high?
Vytrus Biotech's current Marketable Securities is €0.00 Mil. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Marketable Securities compare to VRTX and REGN?
Vytrus Biotech's Marketable Securities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vytrus Biotech and its competitors. Vytrus Biotech's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.59, compared to a current price of €17.40 — trading 211.3% above its estimated fair value. The current Marketable Securities is €0.00 Mil. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Marketable Securities is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €17.40 is trading 211.3% above its estimated GF Value™ of €5.59. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for XMAD:VYT:

  • Marketable Securities: €0.00 Mil
  • GF Value™: €5.59 vs. price of €17.40 (211.3% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vytrus Biotech Business Description

Other Exchanges V5P:Germany
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score

Get the complete analysis for XMAD:VYT

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.40
Price
€5.59
GF Value